Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Aug 5;430(7000):631-9.
doi: 10.1038/nature02621.

Pathways towards and away from Alzheimer's disease

Affiliations
Review

Pathways towards and away from Alzheimer's disease

Mark P Mattson. Nature. .

Abstract

Slowly but surely, Alzheimer's disease (AD) patients lose their memory and their cognitive abilities, and even their personalities may change dramatically. These changes are due to the progressive dysfunction and death of nerve cells that are responsible for the storage and processing of information. Although drugs can temporarily improve memory, at present there are no treatments that can stop or reverse the inexorable neurodegenerative process. But rapid progress towards understanding the cellular and molecular alterations that are responsible for the neuron's demise may soon help in developing effective preventative and therapeutic strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The pathology of Alzheimer’s disease
amyloid plaques, neurofibrillary tangles and degeneration of multiple neurotransmitter systems. a. A tissue section from region CA1 of the hippocampus of an Alzheimer’s patient exhibits many neurofibrillary tangle-bearing pyramidal neurons and neuritic plaques, examples of which are demarcated. In addition, diffuse amyloid deposits (yellow) are present. b. Hippocampal pyramidal neurons receive synaptic inputs from several different types of neurotransmitters including excitatory glutamatergic and inhibitory GABAergic inputs from intrinsic hippocampal neurons, and modulatory inputs from cholinergic neurons in the basal forebrain, serotonergic neurons in the raphe nucleus and noradrenergic neurons in the locus ceruleus..
Figure 2
Figure 2. The neurotoxic action of Aβ involves generation of reactive oxygen species and disruption of cellular calcium homeostasis
Interactions of Aβ oligomers and Fe2+ or Cu+ generates H2O2. When Aβ aggregation occurs at the cell membrane, membrane-associated oxidative stress (MAOS) results in lipid peroxidation and the consequent generation of 4-hydroxynonenal (4HNE) a neurotoxic aldehyde that covalently modifies proteins on cysteine, lysine and histidine residues. Some of the proteins oxidatively modified by this Aβ-induced oxidative stress include membrane transporters (left), receptors (R), GTP-binding proteins (g) and ion channels. Oxidative modifications of tau by 4HNE and other reactive oxygen species (ROS) can promote its aggregation and may thereby induce the formation of neurofibrillary tangles. Aβ can also cause mitochondrial oxidative stress and dysregulation of Ca2+ homeostasis resulting in impairment of the electron transport chain (ETC), increased production of superoxide anion radical. and decreased production of ATP. Superoxide is converted to H2O2 by the activity of superoxide dismutases (SOD) and superoxide can also interact with nitric oxide (NO) to produce peroxynitrite (ONOO*). Interaction of H2O2 with Fe2+ or Cu+ generates hydroxyl radical (OH*) a highly reactive oxyradical and potent inducer of MAOS which contributes to the dysfunction of the endoplasmic reticulum (ER).
Figure 3
Figure 3. Strategies and targets for the prevention and treatment of AD
Approaches that are being tested in clinical and/or primary prevention trials include Aβ immunization, Cu+/Fe2+ chelation, cholesterol-lowering drugs (statins), anti-inflammatory agents, antioxidants and folic acid. Epidemiological and animal studies suggest the potential benefits of cognitive stimulation, regular physical exercise and dietary restriction, but these remain to be critically examined in controlled prospective studies or clinical trials.

Similar articles

Cited by

References

    1. Dickson DW. Neuropathological diagnosis of Alzheimer’s disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging. 1997;18:S21–26. - PubMed
    1. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer’s disease. J Neural Transm Suppl. 1998;53:127–140. - PubMed
    1. Selkoe DJ, Schenk D. Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 2003;43:545–584. - PubMed
    1. Hardy J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci. 1997;20:154–159. - PubMed
    1. Sherrington R, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature. 1995;375:754–760. - PubMed